Our news
- 18/07/2019: Pharegis implemented optimized procedures for state registration of pharmaceuticals in Eurasian Economic Union.
- 20/06/2019: Pharegis updated timelines and practical approaches for Russian and EEU GMP inspection applications and procedures.
- 03/04/2019: Renewed general monographs of Russian state pharmacopeia XIV ed. have been analyzed.
Contact us
- Phone/fax: +7 495 442 37 85
- Phone: +7 985 908 58 18
- E-mail: info@regdrug.com
- pharegis.com | regdrug.com
Activities
Regulatory Events Russia
Russian Regulatory News
Pharegis LLC / ООО "Фареджис"
-
- Business address:
3-1 Begovaya str. ("NordStar Tower", 31st flr), Moscow, Russia 125284
Legal & postal address:
11A-11 Cherkizovskaya B. str., Moscow, Russia 107392
PSRN: 1157746918933
TAX ID (TIN): 7718278100
D-U-N-S: 362071645
-
- +7 495 442 37 85 9am-6pm GMT+3
-
- + 7 495 442 37 85
-
- + 7 985 908 58 18
- http://www.pharegis.com
Regulatory news
Drugs.com - New Drug Approvals
- FDA Approves Gemtesa (vibegron) Tablets for the Treatment of Patients with Overactive Bladder (OAB)
- FDA Approves Kineret (anakinra) for the Treatment of Deficiency of IL-1 Receptor Antagonist (DIRA)
- Tagrisso Approved in the US for the Adjuvant Treatment of Patients with Early-Stage EGFR-Mutated Non-Small Cell Lung Cancer
- FDA Approves Pediatric Indication for Xeomin (incobotulinumtoxina) for the Treatment of Chronic Sialorrhea
- FDA Approves Ebanga (ansuvimab-zykl) for the Treatment of Zaire Ebolavirus Infection
News and press releases
- Cyberattack on EMA - update 5, , 15/01/2021
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 11-14 January 2021, PRAC, 15/01/2021
- Cyberattack on EMA - update 4, , 12/01/2021
- EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca, , 12/01/2021
Drugs.com - Clinical Trials
- Harpoon Therapeutics Granted Orphan Drug Designation from FDA for HPN217 for Treatment of Multiple Myeloma SOUTH SAN FRANCISCO,...
- Marinus Pharmaceuticals Receives Positive Response from FDA on Sufficiency of One Phase 3 Clinical Trial for Filing of New Drug Application (NDA) for the Use of Ganaxolone in CDKL5 Deficiency Disorder (CDD) RADNOR, Pa.--(BUSINESS WIRE)...
- Swissmedic Authorizes COVID-19 Vaccine Moderna for Use in Switzerland CAMBRIDGE, Mass.--(BUSINESS...
- U.S. FDA Accepts for Priority Review the Biologics License Application for V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine, for Use in Adults 18 Years of Age and Older KENILWORTH,...
PharmaTimes: PharmaTimes Website RSS
- Boehringer Ingelheim and Enara Bio join forces to discover cancer immunotherapies
- Verona completes enrolment in pilot study of potential COVID-19 inhaler
- US breakthrough designation for ligelizumab in chronic spontaneous urticaria
- NICE backs GSK’s Zejula in advanced ovarian cancer
- NHS England selects supermarket Asda to operate COVID-19 vaccination centre